What is Biomea Fusion, Inc.'s market cap?

Biomea Fusion, Inc. (BMEA) has a market capitalization of $90.4M and trades on NASDAQ.

Who are Biomea Fusion, Inc.'s competitors?

Biomea Fusion, Inc.'s key competitors include Eli Lilly and Company, Viking Therapeutics, Inc, iBio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Biomea Fusion, Inc. partner with?

Biomea Fusion, Inc.'s notable partners include Gilead Sciences, Inc., AbbVie Inc., Johnson & Johnson.

Where is Biomea Fusion, Inc. headquartered?

Biomea Fusion, Inc. is headquartered in United States of America and employs approximately 110 people. It has been publicly traded since 2021.

Biomea Fusion, Inc.

BMEA

Biomea Fusion is a clinical-stage biotechnology company specializing in the discovery and development of oral, small molecule covalent medicines for metabolic diseases.

Market cap

$90.37M-4.5%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

EPS-$0.17Beat by $0.07

Read the full report

Next report

Aug 4, 2026 (In 5 days)

EPS estimate-$0.21

Competitors

By market cap

Eli Lilly$1.09T+58.9%

Viking Therapeutics$3.9B+6.2%

VAN

Vivani Medical$113.0M+27.1%

Biomea Fusion, Inc.$90.4M-3.9%

iBio$69.1M+517%

Palatin Technologies$13.7M—

MTV

MetaVia$7.4M-40.6%

Alaunos Therapeutics$4.6M+2.2%

By net margin

Eli Lilly34.99%+12.3pp

VAN

Vivani Medical-994.14%—

Profile

Biomea Fusion is a clinical-stage biotechnology company specializing in the discovery and development of oral, small molecule covalent medicines for metabolic diseases. The company leverages its proprietary FUSION System to create targeted therapies that aim to restore metabolic health by regenerating functional beta cell mass. Its primary focus is on treating type 1 and type 2 diabetes and obesity through novel mechanisms of action.

Competitive position

A clinical-stage pioneer in developing irreversible covalent binders specifically against menin for the treatment of diabetes.

GeographiesUnited States

Customer segmentsEndocrinologists, Metabolic disease patients

Business modelR&D-stage biotechnology, Drug development

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Raw material and starting material suppliers

CustomersEndocrinologists, Specialty pharmaceutical distributors, Third-party payors

CountryUnited States of America

Listed2021

Employees110.0

CEOMichael J. Hitchcock

SectorHealthcare

IndustryBiotechnology

Websitebiomeafusion.com

FilingsSEC EDGAR

Questions, answered.

What is Biomea Fusion, Inc.'s market cap?: Biomea Fusion, Inc. (BMEA) has a market capitalization of $90.4M and trades on NASDAQ.
Who are Biomea Fusion, Inc.'s competitors?: Biomea Fusion, Inc.'s key competitors include Eli Lilly and Company, Viking Therapeutics, Inc, iBio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Biomea Fusion, Inc. partner with?: Biomea Fusion, Inc.'s notable partners include Gilead Sciences, Inc., AbbVie Inc., Johnson & Johnson.
Where is Biomea Fusion, Inc. headquartered?: Biomea Fusion, Inc. is headquartered in United States of America and employs approximately 110 people. It has been publicly traded since 2021.